PMID- 9637766
OWN - NLM
STAT- MEDLINE
DCOM- 19980730
LR  - 20201219
IS  - 0008-8749 (Print)
IS  - 0008-8749 (Linking)
VI  - 186
IP  - 1
DP  - 1998 May 25
TI  - Human dendritic cells, pulsed with either melanoma tumor cell lysates or the 
      gp100 peptide(280-288), induce pairs of T-cell cultures with similar phenotype 
      and lytic activity.
PG  - 63-74
AB  - Dendritic cells (DCs) pulsed with unfractionated tumor cell lysates or defined 
      tumor peptides provide potent vaccines which elicit strong antitumor immunity. In 
      this study, we generated DCs from the 2-h adherent progenitor cells obtained from 
      the peripheral blood of melanoma patients. These DCs were able to capture 
      biotinylated melanoma tumor cell lysates. We examined the efficacy of immunogens 
      composed of DCs loaded either with the melanoma peptide gp100 [amino acids 
      280-288 (DC/gp100)] or with lysates from melanoma tumor cells (DC/lysates) in 
      inducing cytotoxic T-cells from autologous PBLs of HLA-A2 melanoma patients. 
      After four to five weekly stimulations of bulk PBLs with DC/gp100 or DC/lysates, 
      the cultures were enriched with CD3+ T-cells and exhibited one of three 
      phenotypic and functional patterns: (1) Predominant expression of CD8+ and MHC 
      class I-restricted CTLs which displayed strong lytic activity against melanoma 
      cells and T2 cells loaded with the gp100 peptide, (2) mixed CD4+/CD8+ phenotype 
      and weak lytic activity, or (3) nonlytic and predominantly CD4+ cultures. 
      Interestingly, T-cell cultures from each patient exhibited similar phenotypes and 
      lytic activities whether the stimulant was DC/gp100 or DC/cell lysates. Our study 
      demonstrates that DCs pulsed with soluble melanoma peptides or cell lysates are 
      capable of inducing CD8+ CTLs from autologous PBLs of some, but not all, melanoma 
      patients. The function and phenotype of the generated T-cell cultures are 
      governed by DCs since both antigens (the gp100 peptide and melanoma lysates), 
      when presented by a given DC preparation, induced similar T-cell cultures. In 
      summary, it may be difficult to predict the nature of the cellular responses 
      elicited by DC/tumor antigen vaccines from patient to patient.
FAU - Abdel-Wahab, Z
AU  - Abdel-Wahab Z
AD  - Department of Surgery, Duke University Medical Center, Durham, North Carolina 
      27710, USA.
FAU - DeMatos, P
AU  - DeMatos P
FAU - Hester, D
AU  - Hester D
FAU - Dong, X D
AU  - Dong XD
FAU - Seigler, H F
AU  - Seigler HF
LA  - eng
GR  - R01-CA 64959/CA/NCI NIH HHS/United States
PT  - Journal Article
PT  - Research Support, U.S. Gov't, Non-P.H.S.
PT  - Research Support, U.S. Gov't, P.H.S.
PL  - Netherlands
TA  - Cell Immunol
JT  - Cellular immunology
JID - 1246405
RN  - 0 (Antigens, Neoplasm)
RN  - 0 (Membrane Glycoproteins)
RN  - 0 (Neoplasm Proteins)
RN  - 0 (PMEL protein, human)
RN  - 0 (Peptides)
RN  - 0 (gp100 Melanoma Antigen)
SB  - IM
MH  - Antigens, Neoplasm/immunology
MH  - CD4-Positive T-Lymphocytes/immunology
MH  - CD8-Positive T-Lymphocytes/immunology
MH  - Cell Culture Techniques
MH  - Cell Division
MH  - Cytotoxicity Tests, Immunologic
MH  - Dendritic Cells/*immunology
MH  - Hematopoietic Stem Cells/immunology
MH  - Humans
MH  - Immunophenotyping
MH  - Leukocytes, Mononuclear/immunology
MH  - Melanoma/*immunology
MH  - Membrane Glycoproteins/*immunology
MH  - Neoplasm Proteins/*immunology
MH  - Peptides/*immunology
MH  - T-Lymphocytes/*immunology
MH  - Tumor Cells, Cultured
MH  - gp100 Melanoma Antigen
EDAT- 1998/06/25 00:00
MHDA- 1998/06/25 00:01
CRDT- 1998/06/25 00:00
PHST- 1998/06/25 00:00 [pubmed]
PHST- 1998/06/25 00:01 [medline]
PHST- 1998/06/25 00:00 [entrez]
AID - S0008-8749(98)91298-9 [pii]
AID - 10.1006/cimm.1998.1298 [doi]
PST - ppublish
SO  - Cell Immunol. 1998 May 25;186(1):63-74. doi: 10.1006/cimm.1998.1298.